Stockscreener 앱 받기
5.57
0.18%
-0.010
Insight Molecular Diagnostics Inc 주식(IMDX)의 최신 뉴스
Insider Stock Purchases: February 13, 2026 - Quiver Quantitative
Of Note: Nashville Zoo adds to board - Nashville Post
Insight Molecular Diagnostics Raises Capital to Advance Transplant R&D - TipRanks
Insight Molecular Diagnostics Signs Multiple Material Agreements - TradingView
From $54B to $85B: A Promising Decade for North America IVD - Business Upturn
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Imdx announces $26.0 million registered direct offering - marketscreener.com
Insight Molecular Diagnostics (IMDX) Secures $26M in Direct Stoc - GuruFocus
Insight Molecular Diagnostics prices $26M registered direct offering; shares down - MSN
Insight Molecular Diagnostics Provides Updated Investor Presentation Materials - TipRanks
iMDx lines up $26M to expand GraftAssure into heart transplants - Stock Titan
iMDx Announces $26.0 Million Registered Direct Offering - Sahm
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Boston Scientific (BSX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Steris (STE) and Roche Holding AG (OtherRHHVF) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Stryker (SYK), NewAmsterdam Pharma Company (NAMS) and Resmed (RMD) - The Globe and Mail
Gastric Cancer Diagnostic Procedure Market to Grow at a CAGR of 6.53% - industrytoday.co.uk
Bullish Insight Molecular Diagnostics Insiders Rewarded As Their Investment Rises To US$8.13m - simplywall.st
Analysts Offer Insights on Healthcare Companies: BillionToOne, Inc. Class A (BLLN) and Dexcom (DXCM) - The Globe and Mail
IMDX Supports AST and ASHI STAR Working Group's Call for Decentralized Transplant Monitoring - marketscreener.com
Insight ‘congratulated’ STAR working group on organ health testing paper - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Inogen (INGN), Exelixis (EXEL) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring - marketscreener.com
iMDx Announces 'JPM Week” and 'BTIG Snowbird” Conference Participation - The Manila Times
iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation - GlobeNewswire
iMDx to Welcome Industry Veteran as Vice President of - GlobeNewswire
iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch - Sahm
Is Insight Molecular Diagnostics Inc. (7OC0) stock considered safe haven2026 world cup usa national team quarterfinals midfield engines low block defense group prediction preview - Улправда
Needham reiterates Buy rating on Insight Molecular stock, cites progress on GraftAssureDx - Investing.com Nigeria
Insight Molecular Diagnostics Inc. Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion - marketscreener.com
Insight Molecular Diagnostics (IMDX) Nears Key FDA Submission Mi - GuruFocus
IMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion - MarketScreener
iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion - Sahm
iMDx Stock Rebounds After-Hours As Study Shows Transplant Test Works As Well As Market Standard - MSN
Prostate Cancer Diagnostics Market Size Report, 2026 – 2035 - Global Market Insights Inc.
Insight Molecular Diagnostics Inc.Common Stock (NQ: IMDX - FinancialContent
KIFFIK Biomedical Closes Oversubscribed Series A to Advance Real-Time Molecular Diagnostics Platform - newarkadvocate.com
Insiders Rewarded With US$5.2m Addition To Investment As Insight Molecular Diagnostics Stock Hits US$183m - Yahoo Finance
Molecular Cytogenetics Market Analysis Reveals Growth - openPR.com
Insight Molecular (IMDX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Insight Molecular Diagnostics (FRA:7OC0) EV-to-OCF : -5.98 (As of Dec. 24, 2025) - GuruFocus
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), MDxHealth (MDXH) and RxSight (RXST) - The Globe and Mail
Hedge funds investors control 50% of Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) and were rewarded last week after stock increased 11% - simplywall.st
Animal Health Market Size, Share & Industry Trends Analysis Report [2032] - Fortune Business Insights
Why Insight Molecular Diagnostics Inc. (7OC0) stock attracts HNW investorsQuarterly Risk Review & Verified Short-Term Trading Plans - DonanımHaber
0.00%
1.13%
자본화:
|
볼륨(24시간):